Objective: The aim of this study was to determine whether aggressive management of neuroendocrine hepatic metastases improves survival. Summary Background Data: Survival in patients with carcinoid and pancreatic neuroendocrine tumors is significantly better than adenocarcinomas arising from the same organs. However, survival and quality of life are diminished in patients with neuroendocrine hepatic metastases. In recent years, aggressive treatment of hepatic neuroendocrine tumors has been shown to relieve symptoms. Minimal data are available, however, to document improved survival with this approach. Methods: The records of patients with carcinoid (n ϭ 84) and pancreatic neuroendocrine tumors (n ϭ 69) managed at our institution from January 1990 through July 2004 were reviewed. Eightyfour patients had malignant tumors, and hepatic metastases were present in 60 of these patients. Of these 60 patients, 23 received no aggressive treatment of their liver metastases, 19 were treated with hepatic resection and/or ablation, and 18 were managed with transarterial chemoembolization (TACE) frequently (n ϭ 11) in addition to resection and/or ablation. These groups did not differ with respect to age, gender, tumor type, or extent of liver involvement. Results: Median and 5-year survival were 20 months and 25% for the Nonaggressive group, Ͼ96 months and 72% for the Resection/ Ablation group, and 50 months and 50% for the TACE group. The survival for the Resection/Ablation and the TACE groups was significantly better (P Ͻ 0.05) when compared with the Nonaggressive group. Patients with more than 50% liver involvement had a poor outcome (P Ͻ 0.001). Conclusions: These data suggest that aggressive management of neuroendocrine hepatic metastases does improve survival, that chemoembolization increases the patient population eligible for this strategy, and that patients with more than 50% liver involvement may not benefit from an aggressive approach. (Ann Surg 2005;241: 776 -785) From the **P Ͻ 0.05 versus benign, n ϭ 69 (data not shown). † Including appendix. ‡ P Ͻ 0.05 versus functioning malignant. § P Ͻ 0.05 versus functioning hepatic metastases. *P Ͻ 0.05 versus nonaggressive. † P Ͻ 0.05 versus TACE Ϯ resection/ablation.
N euroendocrine tumors are rare neoplasms that typically have an indolent natural history. Gastrointestinal carcinoid and pancreatic islet cell tumors tend to behave similarly, with survival in patients with these tumors being significantly better than adenocarcinomas arising from the same organs. 1 However, these tumors frequently metastasize to regional lymph nodes, the bones, and the liver. In addition, neuroendocrine hepatic metastases can lead to incapacitating symptoms and can also decrease long-term survival. [2] [3] [4] [5] [6] [7] With improved safety of liver resection and advances in technology, treatment of liver tumors has evolved into a more aggressive, multimodality approach, incorporating surgery, ablative techniques, and transarterial chemoembolization (TACE). 8, 9 Resection, ablation, and TACE for neuroendocrine hepatic metastases have been shown to be an extremely effective treatment of the symptoms related to the metastases. However, minimal data are available to document improved survival when an aggressive treatment strategy is employed. Therefore, the aim of this study was to determine if aggressive management of neuroendocrine hepatic metastases prolongs survival.
METHODS

Patient Population
A retrospective study was performed of all patients with neuroendocrine tumors treated over a 15-year period from January 1990 through August 2004 at the Froedtert Memorial Hospital (FMH) and the Medical College of Wisconsin. The FMH institutional review board granted approval for the protocol. The electronic medical records, clinic charts, pathology reports, and the cancer registry were used to determine patient demographic, pathology, treatment, and outcomes data. One hundred fifty-three patients with neuroendocrine tumors were identified ( Table 1 ). The mean age was 55 years, with a relatively equal distribution of men and women. Eighty-four patients (55%) were found to have carcinoid tumors, while 69 (45%) patients had pancreatic neuroendocrine tumors. Malignant tumors, defined as any positive locoregional lymph nodes or the presence of distant metastasis, made up 55% (n ϭ 84) of the patient population.
The malignant group had similar demographics with the group as a whole with respect to gender and percentage carcinoid and pancreatic tumors (Table 1 ). However, this group was significantly older (P Ͻ 0.05) when compared with the patients with benign tumors (n ϭ 69). Pancreatic tumors in the malignant group were significantly more likely (P Ͻ 0.05) to be nonfunctioning tumors rather than functioning tumors (27% versus 14%). Of the 84 patient in the malignant group, 21% (n ϭ 18) were malignant based on positive lymph nodes only, with the remainder of the group having distant metastatic disease. Sixty patients were identified with hepatic metastases. This subgroup of hepatic metastases patients was similar to the group as a whole with respect to age, gender, and tumor type. However, this group was more likely (P Ͻ 0.05) to have pancreatic tumors that were nonfunctioning rather than functioning (33% versus 7%). Fifty percent of the hepatic metastases group (n ϭ 30) had metastases outside of the liver.
This series of neuroendocrine patients is similar to many in the literature, [2] [3] [4] [5] with relatively good 5-year survival. Figure 1A compares the 69 benign patients with the 84 malignant patients in the entire series. Five-year survival was significantly better (P Ͻ 0.001) in the benign group (91%) versus the malignant group (56%). For the 60 patients with hepatic metastases, no difference in 5-year survival was observed between those with carcinoid (n ϭ 36) and pancreatic (n ϭ 24) tumors ( Fig. 1B) . Therefore, these 2 groups were combined for the evaluation of treatment outcomes.
Hepatic Metastases Management
The hepatic metastases group was further broken down into 3 groups: Nonaggressive, Resection/Ablation (RA), and TACE Ϯ RA. The RA and the TACE Ϯ groups were considered the aggressively treated groups. The Nonaggressive group consisted of 23 patients who may have undergone resection for their primary tumor but did not have aggressive treatment of the hepatic disease ( Table 2 ). The RA group included 19 patients who received either surgical resection (n ϭ 18) and/or cryoablation (n ϭ 13) for treatment of their hepatic neuroendocrine metastases, as previously described. 10 The TACE group included 18 patients who underwent a mean of 3.2 Ϯ 2.2 TACE procedures with cisplatin, adriamycin, and mitomycin C, as previously described (Kiely et al, unpublished data). Eleven of these patients also underwent surgical resection, while 5 had cryoabalation of liver metastasis. These 3 groups did not differ with respect to mean age, gender, or tumor type ( Table 2) . Four parameters of liver tumor burden were evaluated: more than 50% liver involvement, unilobar versus bilobar disease, size of the largest tumor, and total number of tumors. For all 60 patients with hepatic metastases, 22% had more than 50% liver involvement, 68% had bilobar disease, the mean tumor size was 5.1 Ϯ 0.7 cm, and the mean tumor number was 7.5 Ϯ 1.0. The 3 treatment groups did not differ with respect to any parameters of liver involvement ( Table 2) . For all 60 patients, the liver metastases were diagnosed synchronously in 77%, 50% had nonliver metastases, and 77% were symptomatic. Again, the 3 treatment groups did not differ with respect to metastatic disease, symptoms, or radiologic workup (Table 2) .
Patients in the RA group (89%) and the TACE Ϯ RA group (61%) were more likely (P Ͻ 0.05) to have the primary tumor resected compared with the Nonaggressive group (43%) ( Table 3 ). Conversely, the Nonaggressive group was more likely (P Ͻ 0.05) to receive systemic chemotherapy than the RA (18%) or TACE Ϯ RA (9%) group. Radiation therapy was employed in only 17%, and octreotide was used in only 23% of the liver metastases patients, with no differences among the 3 treatment groups ( Table 3 ). Only 21% of the 29 patients undergoing liver surgery had a major resection, whereas 79% had a wedge or segmental resection ( Table 3 ). Cryoablation was employed more frequently (P Ͻ 0.05) in the RA (68%) than in the TACE Ϯ RA group (28%) ( Table 3 ).
Pathology
All specimens were reviewed by the pathologists at our institutions and determined to be neuroendocrine tumors. All neuroendocrine tumors were included in this analysis, including foregut, midgut, hindgut, and pulmonary carcinoids, as well as functional and nonfunctional pancreatic tumors. A malignant tumor was defined as any tumor with positive locoregional lymph nodes or the presence of distant metastasis disease. Pancreatic tumors were stained for a variety of hormones, including gastrin, glucagon, insulin, somatostatin, and vasoactive intestinal peptide. A pancreatic tumor was classified as functional if it stained strongly for a specific hormone or the patient was symptomatic from hormone release.
The 3 hepatic metastases groups were similar to each other with respect to percent carcinoid, percent pancreatic, organ of origin, and percent nonfunctioning tumors ( Table 2 ). The breakdown of these 60 patients was 60% (n ϭ 36) carcinoid and 40% (n ϭ 24) pancreatic. Small-bowel carcinoid tumors (n ϭ 13, 22%) and nonfunctioning pancreatic tumors (n ϭ 20, 33%) were the most common ( Table 2 ). Of the 4 functional pancreatic tumors, 2 were glucagonomas, and 1 each was an insulinoma and a gastrinoma.
Patient Outcome
Morbidity was defined as any complication that occurred during or immediately following any resection, ablation, or chemoembolization. For patients in the Nonaggressive group, only those patients who had resection of their primary tumor were included in the morbidity assessment. Complications included readmission for dehydration, abscess, biloma, intraabdominal bleeding, anastomotic breakdown, pleural effusion/empyema, superior vena cava thrombosis, myocardial infarction, and death. Mortality was characterized as death within 30 days of any resection, ablation, or TACE. All presenting and long-term symptoms due to locoregional invasion, mass effect, or systemic hormone release were evaluated. Alleviation or significant sustained relief of symptoms was considered symptomatic improvement. Follow-up and survival data were obtained on all patients from hospital records, clinic notes, the cancer registry, and the Social Security Death Index Database. For patients in the Nonaggressive group, survival was calculated from the date of primary tumor resection or the date of diagnosis if the primary tumor was not resected. For all patients in the aggressively treated groups, the date of first resection, ablation, or chemoembolization was used as the start date. Survival for any patient who had a long-term, disease-free state (Ͼ10 years) and then presented with metastases was calculated from the date of metastases treatment.
Statistical Analysis
Data are presented as percentages, median or mean Ϯ standard error of the mean. Statistical analyses were performed by analysis of variance, Student t test, and 2 analysis where appropriate, with statistical significance achieved at P Ͻ 0.05. Survival rates were analyzed by the Kaplan-Meier actuarial methods, with statistical significance determined by the log-rank statistic using SPSS statistical software (SPSS Inc., Chicago, IL).
RESULTS
Morbidity and Mortality
The 3 groups were similar with respect to morbidity and mortality ( Table 4 ). Three of the 12 patients (25%) undergoing surgery of the primary tumor in the Nonaggressive group had complications, an anastomotic leak, intraabdominal bleeding, and a subclavian vein thrombosis. Two of the complications, anastomotic leak after colectomy and bleeding following pancreatoduodenectomy, led to patient mortality. Eight of the 19 patients (42%) in the RA group had a complication. Six of the complications, biloma, abscess, atrial fibrillation, pancreatic fistula, and 2 myocardial infarcts, occurred after resections, while 2, hepatic abscess and bleeding, occurred after cryoablation. One patient in this group died after a major hepatectomy. Of the 18 TACE Ϯ RA patients, 5 (28%) had complications, 2 after surgery and 3 following chemoembolization. The 2 surgical complica-tions were readmission for dehydration and lung abscess. Fifty-six chemoembolization procedures were followed by 3 complications (5%): a groin hematoma, a biloma, and death within 30 days of a procedure. The 1 death was secondary to widespread metastatic disease and not due to any direct complication of the procedure. If morbidity was calculated by procedure rather than patient, the TACE Ϯ RA group had fewer complications (P Ͻ 0.05).
Symptomatic Improvement
The Nonaggressive group was significantly less likely (P Ͻ 0.05) to have symptomatic improvement (42%) compared with the RA (95%) or the TACE Ϯ RA (88%) groups ( Table 4 ).
Survival
Overall survival was significantly longer (P Ͻ 0.05) in the 2 aggressively treated groups compared with the Nonaggressive group (Table 4 , Fig. 2 ). The median survival in the 3 groups was 20 months for the Nonaggressive group, Ͼ96 months for RA, and 50 months for TACE Ϯ RA group ( Table 4 ). The Kaplan-Meier survival curve ( Fig. 2 ) reflects this significant difference, along with the 5-year survival of 72% for the RA group, 50% for the TACE Ϯ RA group and 25% for the Nonaggressive group. Survival in the 60 hepatic metastases patients was also analyzed with respect to liver burden. Only greater than 50% involvement had a significant effect (P Ͻ 0.001) on survival (Fig. 3 ). The 5-year survival for patients with less than 50% involvement was 67%, while that for the more than 50% involvement was only 8%. Of these 13 patients with more than 50% liver involvement, 7 were managed nonaggressively, while 6 were treated aggressively. However, only 1 of these 13 patients was alive at 5 years. If these 13 patients were eliminated from the survival analysis, survival was still significantly longer (P Ͻ 0.05) in the aggressively treated than in the non-aggressively treated patients. Bilobar disease, largest tumor size, and number of tumors did not influence survival. 
DISCUSSION
In this series, we reviewed 153 patients with carcinoid and pancreatic neuroendocrine tumors. Of these patients, 60 (39%) had hepatic metastases. These 60 patients were further analyzed based on the treatment they received. The Nonaggressive group (n ϭ 23), the RA group (n ϭ 19), and the TACE Ϯ RA group (n ϭ 18) were similar with respect to age, gender, tumor type, and liver tumor burden. No differences were observed in morbidity or mortality among the 3 groups. However, the aggressively managed patients were more likely (P Ͻ 0.05) to have symptomatic relief and survived significantly (P Ͻ 0.05) longer. The only predictor of de-creased survival with respect to tumor burden was more than 50% hepatic involvement.
Medical, nonaggressive treatment of carcinoid tumors primarily involves chemotherapy and external-beam radiation or hormonal somatostatin analogs, such as octreotide and lantreotide. The principal purpose of these treatments is symptom control and slowing disease growth. 8 However, a recent review of the current management of gastrointestinal carcinoid tumors found that single-agent chemotherapy for unresectable disease is ineffective, while multiagent regimens have only a limited value due to the short duration of response and substantial toxicity. 8, 11, 12 Such multiagent regimens have not proven to significantly improve survival. 11, 12 Furthermore, while external-beam radiation remains a standard for palliation of metastatic brain and bone disease, radiation is not effective for local disease control. 13 Several studies have documented the beneficial effects of octreotide with respect to the relief or reduction of symptoms, improved quality of life, better biochemical profiles, and tumor stabilization, but without actual tumor shrinkage. 8, 14, 15 Similarly, radiolabeled octreotide, while a useful diagnostic and localizing tool, has shown no definite clinical benefit and lacks significant response. 8 In addition, these therapies are not without their complications including biliary sludge, steatorrhea, hyperglycemia, and cardiac conduction abnormalities. 8 Our data confirm the results of these other studies by showing that the Nonaggressive group was less likely to have symptomatic improvement, and overall survival in this group was significantly reduced.
Surgical resection of neuroendocrine hepatic metastases is a proven treatment of symptoms related to systemic hormone release. 3, 16, 17 In the past, liver resections were complex operations that were associated with high morbidity and mortality. However, advances in operative techniques and equipment have made these resections much safer, especially in tertiary, high-volume centers. 3, 18 Although these neuroendocrine tumors are frequently characterized by an indolent course, historic controls with hepatic metastases without resection or ablation have a much-reduced 5-year survival, which varies from 20% to 30%. 4, 16, 19, 20 Recently, several groups have reported improved 5-year survival of 50% to 70% with resection of neuroendocrine hepatic metastases. However, these reports have generally not included data on patients treated less aggressively. 21 Our series adds to this growing body of data supporting surgical resection of neuroendocrine hepatic metastases and documents improved survival compared with nonsurgical patients managed at the same institution.
Ablation of liver tumors using either heat or cold has become more popular in recent years. 9 However, the exact role of tumor ablation in the treatment of neuroendocrine hepatic metastases has yet to be determined. Several groups have shown that ablation of neuroendocrine hepatic tumors 
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Neuroendocrine Hepatic Metastases leads to improved symptomatic control. 22, 23 With increasing data suggesting that surgical debulking of colorectal liver metastases improves survival, the use of ablation for neuroendocrine metastases also seems appropriate. 16 Ablation allows for treatment of smaller metastases which are deep in the liver parenchyma without the need for resection. In addition, ablation can be used as an adjunct to surgery, especially in patients with bilobar involvement and when resection would not leave enough functioning liver. Moreover, the addition of ablation to treatment algorithms allows more patients to be treated aggressively. TACE of liver tumors is a newer modality that has been shown to improve survival in patients with hepatocellular cancer. 24, 25 TACE has also been shown to be a safe modality even in high-risk patients (Kiely et al, unpublished data). Multiple groups have demonstrated that TACE provides symptomatic control in patients with neuroendocrine metastases. 26 In addition, Falconi et al 27 have reported that the combination of surgery and TACE resulted in a 50% 5-year survival in 12 patients with neuroendocrine hepatic metastases. Like ablation, the exact role of TACE in neuroendocrine hepatic lesions is still being elucidated. In some patients, TACE has been employed to convert unresectable to respectable disease. In addition, TACE may be indicated in patients with multiple lesions and/or bilobar disease. We have shown in this analysis that a combination of surgery, ablation, and TACE can be used to make a larger percentage of patients with neuroendocrine metastases eligible for aggressive management while providing a 50% 5-year survival.
In an attempt to surgically treat hepatic metastases, evaluation of the extent and distribution of disease becomes important. The difficulty in treating neuroendocrine metastases is that most of patients will develop multifocal and bilobar disease, making standard resection alone inadequate. 28 In an analysis of 85 patients by Chamberlain et al, 4 84% had bilobar disease, 45% had extrahepatic metastases, and 53% had more than 50% involvement. In the present analysis, survival was evaluated by 4 hepatic tumor parameters. Patients with more than 50% involvement had significantly reduced (P Ͻ 0.001) 5-year survival (8% versus 67%). In comparison, bilobar disease, tumor size, and tumor number did not have a significant effect on survival. This observation suggests that patients with more than 50% liver involvement may not benefit from aggressive surgery, ablation, and/or chemoembolization. For these patients, orthotopic liver transplantation (OLT) may be an option. In one multicenter report from France, OLT for neuroendocrine hepatic metastases had an impressive 5-year survival approaching 70%. 29 However, evaluation of OLT for neuroendocrine metastases is difficult because of variable extent of disease and treatment prior to transplantation. Nevertheless, some transplant groups using the Milan neuroendocrine criteria, which requires no extra-hepatic disease, less than 50% liver involvement, and carcinoid histology, have reported good results. 8 With improved safety of liver surgery and advances in the technology for ablating and embolizing liver tumors, the aggressive treatment of neuroendocrine hepatic metastases has been employed by several groups in recent years. Despite having an indolent course compared with adenocarcinomas, neuroendocrine tumors have a significantly reduced survival when metastases to the liver are present. Resection has been shown to be an excellent treatment of symptoms, and accumulating data document improved survival with resection of these tumors. Moreover, the combination of surgery, ablation, and chemoembolization of hepatic metastases expands the patient pool eligible for aggressive management and results in symptom relief, as well as improved survival.
Discussions
DR. LAYTON F. RIKKERS (MADISON, WISCONSIN): It has been fairly well established that there is a clear survival benefit from aggressive surgical management of patients with colorectal liver metastases. Such a benefit has been much more difficult to demonstrate for metastatic neuroendocrine tumors both because of their indolent biological behavior and their relative infrequency as compared to colorectal carcinoma.
Dr. Pitt and his associates have accumulated an impressive series of over 150 patients with neuroendocrine tumors, and 60 of these patients had concomitant liver metastases. Most of the other reports that we have seen addressing the effect of liver resection for patients with neuroendocrine liver metastases have been in patients with isolated liver metastases. Such was not the case here in that over 50% of these patients also had extrahepatic disease, suggesting that they had more aggressive tumors.
Despite the relatively advanced disease in many of these patients, aggressive surgical management directed toward the liver metastases appeared to significantly prolong survival. In fact, median survival for resected or ablated patients was more than 4 times longer than for the nonaggressively treated patients, several of whom received chemotherapy alone. Patients undergoing chemoembolization also appeared to benefit, but not to the same extent as did the resected patients.
Was the hepatic tumor burden really comparable among the treatment groups? The single strongest negative prognostic factor in this series was a greater than 50% liver involvement by metastatic disease. Across all treatment groups, such patients survived a very brief period of time.
Although not significantly different among the groups, the untreated group had twice as many patients with such extensive hepatic metastatic disease as the 2 other groups who were aggressively treated. If the patients with more than 50% liver involvement in all of the groups are excluded, is there still a detectable survival benefit from liver resection and/or ablation? Additionally, other potential adverse prognostic factors such as number of metastatic tumors within the liver were also more prevalent in the nontreatment group, again suggesting that they may have had more advanced disease. Again, this was not significantly different from the other groups.
One way to objectively assess treatment effects in patients with neuroendocrine tumors is to measure the products of those tumors, many of which cause symptoms. Were hormonal measurements done in the patients in this series? Were chromogranin A levels measured and was the impact of surgery and ablation and chemoembolization ascertained with respect to these markers? DR. C. WRIGHT PINSON (NASHVILLE, TENNESSEE): I agree with the basic tenet that the fairly aggressive approach to these neuroendocrine tumors yields better outcomes than conservative therapy.
However, I do want to ask the authors how we can be assured that this improved result in the aggressively treated group is not due to significant selection biases, given (1) the treatment was not random in this retrospective study; (2) greater than 50% liver involvement was more than twice as common in the nonaggressive group; and (3) there was a higher 30-day mortality in the non-aggressively treated group.
How did you measure clinical improvement such as symptoms in a retrospective review? It seems to me it would be very difficult to evaluate symptoms retrospectively. Wouldn't a scale such as Karnofsky scoring or some other objective measure improve this? Like Dr. Rikkers, I would be interested in neuroendocrine serum markers such as neuron specific enolase, and chromogranin A, 5-HIAA.
My next question has to do with the poor results in the transarterial chemoembolization group plus/minus resection or ablation compared to the resection ablation group alone. Given that the groups are described as equivalent to begin with, why do you not conclude from your work that transarterial chemoembolization is of no benefit and in fact might be slightly detrimental? Is this a selection bias issue again?
You said you concluded that chemoembolization increases the proportion eligible for resection and ablation. And Based on our experience with previous preoperative chemoembolization followed by resection, we found that the chemoembolization made the resection technically more challenging. We have modified our protocols to use preoperative hepatic arterial continuous chemoinfusion for a selected time period to try to decrease tumor burden and afford us more opportunities for resection. And I was wondering if you have modified your protocol any in that scenario.
Also, what is your perioperative octreotide protocol dosing schedule, and have you seen the carcinoid crisis intraoperatively?
And then thirdly, are you currently looking at intracellular levels of staining for KI-67 and chromogranin A to determine perhaps what group might be better candidates for aggressive surgical therapy? The problematic group is that group, as we have found, with greater than 50% hepatic tumor burden. And that seems to be the hardest group to treat. We are looking at ways to try and decrease their tumor burden prior to surgical resection and are faced with some of the similar challenges that I am sure you are seeing.
DR. GERARD M. DOHERTY (ANN ARBOR, MICHIGAN): This
paper is all about selection bias, and I am not sure that the data really support the conclusion that we all think is true.
Maybe we can explore the selection bias a little bit to know more about how the patients got into that resection and ablation category. Many of us think that if we can somehow deal with at least 90% of the patient's disease, we may have some impact on their overall survival. How did your patients get into that resection group, particularly that 40% of them who had extrahepatic metastases present? DR. JAMES G. CHANDLER (BOULDER, COLORADO): I always enjoy Dr. Pitt's group's papers, and this substantial series is no exception. But I wonder if survival is the most descriptive outcome for this group of patients. The protracted growth of neuroendocrine metastases often results in a massive visceral and bony tumor burden well before death intervenes. Bone metastases, in particular, are very painful, requiring mindnumbing narcotics to achieve a barely tolerable and markedly limited lifestyle. Quality life is the real goal of therapy and a more meaningful metric.
DR. HENRY A. PITT (INDIANAPOLIS, INDIANA): Dr.
Rikkers' first question had to do with whether the hepatic tumor burden was comparable among the 3 groups. With respect to greater than 50% involvement, bilobar verus unilateral disease, number of tumors, and size of tumors, we could find no differences. The 3 groups had only 18 to 23 patients, so it is possible that we had a type 2 error and there were differences, but we did not have sufficient power.
He asked also specifically about the patients that had more than 50% involvement and whether the outcome of our study would be the same if those patients were excluded. There were 13 patients that fell into that category, 6 in the nonaggressive group and 7 in either the resection/ablation or the TACE plus resection ablation group. Again, only 1 of those patients was alive at 5 years. If we had excluded those 13 patients, the overall results would have looked a little better, but the differences among the 3 groups still would have been present.
Dr. Rikkers, Dr. Pinson, and Dr. Boudreaux also asked about tumor markers. A number of tumor markers exist, including 5-HIAA, chromogranin A, neuron specific enolase, and in selected cases various hormones, as well as KI-67. We have a modest amount of data on many of these markers in these patients. However, we do not have a complete data set on enough patients over the 5 to 7 years of follow-up to draw any good conclusions.
A key question again from Dr. Pinson and Dr. Doherty, as well as Dr. Rikkers, was the potential for selection bias and whether these groups really are comparable. Again, with respect to age, gender, tumor type, liver involvement, the presence of extrahepatic disease, and symptoms, we could find no differences among the 3 groups. The one factor that was different was that only 43% of the nonaggressive group had had their primary tumor resected versus 76% of the other 2 groups combined. This difference does suggest that a bias may have existed. This study is retrospective, not a prospective randomized study. While we would all like to see a prospective, randomized study, such a study is very hard to do. In these rare lesions, you are lucky to accumulate a series over 15 years. The nonaggressive group was more likely to be referred to a medical oncologist than to an aggressive surgeon, so this bias also existed. The surgeons and interventional radiologists tended to treat these patients more aggressively, whereas our medical oncologists were more likely to give chemotherapy.
With respect to clinical outcomes, which was mentioned both by Dr. Pinson and Dr. Chandler, having good prospectively gathered data on quality of life would be ideal. They are absolutely correct that it is difficult to access quality of life from the charts and the clinical notes. We analyzed the data very carefully to document whether pain was improved and whether carcinoid symptoms were improved. Our data are as good as possible from a retrospective series. We did show a difference among the 3 groups, with the aggressively treated patients having a 90% improvement in symptoms versus only a third of the nonaggressive group. Dr. Pinson's group recently reported their prospective evaluation of Karnofsky data on a number of their patients and documented that the more of the liver tumor burden you were able to ablate or resect, the more likely that the quality of life was going to improve. I would argue, however, that the Karnofsky scores assigned by a physician or nurse are not as accurate as quality of life measures like the SF-36, which is the patient's own measure of their quality of life.
Again, Dr. Pinson asked about TACE and whether survival was improved versus a selection bias or not. In comparing the TACE group versus the resection/ablation group, the resection/ablation patients had a better survival but this difference was not statistically significant. However, survival for each of these groups was significant versus the nonaggressive group. Thus, we concluded that TACE did help these patients.
TACE does expand the patients eligible for aggressive management. TACE is appropriate for patients with bilobar disease and those patients that have a big tumor that is not initially resectable but may be reduced in size and become resectable. In addition, of those patients who have had a couple of operations and have symptoms recur, TACE may provide further palliation and may prolong survival.
The role of transplantation is equally unclear. A nice French multiinstitutional report of 31 patients with a 70% 5-year survival was recently published. They selected patients by the Milan criteria for neuroendocrine tumors, which includes carcinoid tumors with no extrahepatic disease, which was present in 50% of our patients, a good response to other treatments, like TACE, and less than 50% liver involvement. Thus, the French have applied transplantation to a group of patients who would be expected to have a very good result from resection, ablation, or TACE. Thus, we really do not know the role of transplantation, and randomized data are needed here as well.
With respect to Dr. Boudreaux's question on perioperative octreotide, we have not used it routinely. However, we have not seen a crisis in these patients.
